Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,773 INR
Change Today 0.00 / 0.00%
Volume 0.0
LPC On Other Exchanges
Symbol
Exchange
Natl India
OTC US
As of 7:06 AM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).

lupin ltd (LPC) Snapshot

Open
1,750
Previous Close
1,744
Day High
1,785
Day Low
1,730
52 Week High
04/8/15 - 2,115
52 Week Low
05/26/14 - 902.60
Market Cap
797.3B
Average Volume 10 Days
2.0M
EPS TTM
40.99
Shares Outstanding
449.8M
EX-Date
07/21/14
P/E TM
43.2x
Dividend
3.00
Dividend Yield
0.17%
Current Stock Chart for LUPIN LTD (LPC)

Related News

No related news articles were found.

lupin ltd (LPC) Related Businessweek News

No Related Businessweek News Found

lupin ltd (LPC) Details

Lupin Limited, a pharmaceutical company, produces, develops, and markets a range of branded and generic formulations and active pharmaceutical ingredients (APIs) primarily in India, the United States, and Japan. It offers various formulations for use in the areas of cephalosporin, cardiovascular (CVS), central nervous system (CNS), anti-asthma, anti-tuberculosis, diabetology, dermatology, gastro intestinal, and other therapy segments; and APIs for use in therapeutic areas of antibiotics, anti-tuberculosis, CVS, CNS, analgesics, and anti-gout. The company also develops and out-licenses its drug delivery technologies and platforms; and creates and develops biosimilars for various therapeutic indications, such as oncology, inflammation, antivirals, osteoporosis, and rheumatoid arthritis. In addition, it is engaged in the novel drug discovery and development programs for use in the treatment of metabolic disorders, pain and inflammation, autoimmune diseases, CNS disorders, cancer, and infectious diseases. Lupin Limited has strategic development and licensing agreement with Celon Pharma S.A. to develop fluticasone/salmeterol dry powder inhaler product that is a generic version of GlaxoSmithKline’s Advair Diskus; and strategic partnership with Merck Serono S.A. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

15,000 Employees
Last Reported Date: 05/7/14
Founded in 1968

lupin ltd (LPC) Top Compensated Officers

Founder, Chairman, Member of Share Transfer C...
Total Annual Compensation: 31.8M
Managing Director and Executive Director
Total Annual Compensation: 52.4M
Executive Director, Member of Share Transfer ...
Total Annual Compensation: 3.6M
Compensation as of Fiscal Year 2014.

lupin ltd (LPC) Key Developments

Lupin Limited Introduces Hepatic Encephalopathy Treatment Zaxine in Canada

Lupin Limited introduced its first brand product, Zaxine, in Canada Zaxine 550mg (rifaximin) is a long-term antibiotic treatment for adult patients with hepatic encephalopathy (HE), a complication of liver disease (cirrhosis). HE will result in a wide spectrum of mental and physical symptoms, including confusion, disruption in sleep patterns and personality changes. Lupin Pharma Canada has launched the product in the country, as part of a strategic licensing agreement with US-based gastrointestinal (GI) specialty firm Salix Pharmaceuticals.

Lupin Limited, Board Meeting, Mar 24, 2015

Lupin Limited, Board Meeting, Mar 24, 2015. Agenda: To discuss and approve allotment of fully paid up equity shares.

Lupin Ltd Appoints Theresa Stevens as Chief Corporate Development Officer

Lupin Ltd. has decided to acquire the rest equity stake of the Pharma Dynamics (PD) to make it a 100% arm of the company. Despite its involvement in inorganic expansion during 2007-11, Lupin has been inactive on the M&A space since then. But, it stimulated its M&A-focused growth strategy in early 2014 with its purchase of Laboratorios Grin S.A. De C.V. Besides, Lupin's purchase of Nanomi B.V of the Netherlands facilitated the company to produce complex injectables with new drug delivery systems. The deployment of the Dutch firm's proprietary technology platform will enable Lupin to make major inroads into the niche complex injectables field. Lupin appointed Theresa Stevens as its Chief Corporate Development Officer following these two purchase deals.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LPC:IN 1,772.55 INR +28.45

LPC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $59.10 USD +3.73
H Lundbeck A/S kr129.40 DKK +0.80
Ipca Laboratories Ltd 642.10 INR 0.00
Krka dd Novo mesto €68.65 EUR +0.64
Piramal Enterprises Ltd 938.10 INR 0.00
View Industry Companies
 

Industry Analysis

LPC

Industry Average

Valuation LPC Industry Range
Price/Earnings 32.9x
Price/Sales 6.2x
Price/Book 9.7x
Price/Cash Flow 28.2x
TEV/Sales 6.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUPIN LTD, please visit www.lupinworld.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.